What stage does OCV Partners invest at?

OCV Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is OCV Partners located?

OCV Partners is headquartered in Los Angeles, US.

Does OCV Partners lead rounds?

Yes, OCV Partners leads investment rounds.

OCV Partners

Venture capital

Los Angeles · Pre-Seed–Late Stage · 5 people tracked

Also known as OCV MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

OCV Partners invests in brilliant teams building disruptive technology, drawing on the partners' background as former founders who have grown businesses from early stages through IPOs. Its core focus areas are Technology (SaaS, FinTech, and PropTech), with expertise in subscription and recurring-revenue software models, and Healthcare (Healthcare SaaS, Digital Health, MedTech, and BioTech). In healthcare, the firm backs companies enabling precision and targeted approaches, empowering better treatment decisions, removing barriers to equitable care, and expediting discovery of new treatments. OCV aims to create asymmetric advantages for founders and offers flexible capital, preferring but not requiring to lead rounds.

Invests inAI & Machine Learning Biotech Digital Health Enterprise Software Fintech Healthtech Medical Devices PropTech SaaSLos AngelesUnited States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Late Stage

Los Angeles, CA, US

Leads rounds

Leads

Instruments

Equity

Private fund assets

$172.9M

VC funds

Tracked investments

Team · 5 people

from the firm's website & public directories

Richard Ressler· Co-Founder, Chairman· Los Angeles, CA

Richard Ressler co-founded OCV in 2016 and chairs its executive committee through an agreement with Orchard Capital. He also co-founded CIM in 1994 and the predecessor of OFSAM in 2001, chairing committees at both, with a career focused on real asset, infrastructure, and credit investing. Earlier he served as Vice Chairman of Brooke Group Limited (predecessor of Vector Group), worked at Drexel Burnham Lambert on M&A and middle-market financing, and began his career at Cravath, Swaine and Moore. He holds a B.A. from Brown University and J.D. and M.B.A. degrees from Columbia University.

Andy Liu· Partner· Los Angeles, CAin

Andy Liu focuses on software investments at OCV Partners and works on adding operating value across the portfolio. He previously worked in Morgan Stanley's technology investment banking group covering SaaS and FinTech clients, led go-to-market teams at Addepar, and earlier worked in consulting at Deloitte on financial services and technology. He holds an M.B.A. from UC Berkeley Haas and a B.A. in Business Economics from UCLA.

Chris Bostick· Partner· Los Angeles, CAin

Chris Bostick focuses on healthcare investments at OCV Partners, working on technologies that apply interdisciplinary methods to precision medicine. Before joining OCV, he completed postdoctoral work at the Institute for Genomic Medicine at Columbia University, studying precision medicine approaches to genetic neurological disorders, and earlier researched drug metabolism, bioelectronics/biosensors, and nanotechnology during his PhD. He holds a B.S. in Biology with a business minor from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University.

Hemi Zucker· Managing Partner· Los Angeles, CAin

Hemi Zucker co-founded j2 Global in 1996 and served in multiple executive roles including CEO, President, COO, CMO, and CFO during the company's 1999 IPO, leading it through more than 160 acquisitions and expansion into cloud services, patent licensing, and digital media. Before j2, he worked at Motorola in the U.S. and Israel, where he helped launch Israel's first cellular company and worked on early wireless data networks. He holds a B.A. in Economics from Tel Aviv University.

Joe Sassi· Senior Associate· Los Angeles, Californiain

What they invest in

from 9 of 21 portfolio companies

Biotech ×4Healthtech ×4Medical Devices ×2AI & Machine Learning ×1Creator Economy ×1Cybersecurity ×1Deep Tech ×1Developer Tools ×1

HQs:United States×7

Investments · 21 tracked

founders shown can be your intro path

Praxis Precision MedicinesNASDAQ: PRAX

Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.

BiotechCambridge, US

Nicholas G. Galakatos(Director)Kiran Reddy(Executive Officer, Director)

Precision BioSciencesprecisionbiosciences.comin 𝕏NASDAQ: DTIL

Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.

BiotechDeep TechHealthtechDurham, US

JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)

ByHeartbyheart.com

HealthtechNew York, US

Georg Krause-Vilmar(Executive Officer)Amy Schulman(Director)Hemi Zucker(Director)Guy Oranim(Director)Arie Belldegrun(Director)Anton Linderum(Director)

Board seatHemi Zucker· per SEC Form D

MeridianMade, Inc.SEC filingmedium confidence

HealthtechNew York, US

Ron Belldegrun(Executive Officer, Director)Georg Krause-Vilmar(Executive Officer)Mia B. Funt(Executive Officer, Director)Devon Kuehn(Executive Officer)Niall Mullane(Executive Officer)Neil Betteridge(Executive Officer)

Board seatHemi Zucker· per SEC Form D · $20.3M raise · filed Jul 2026

1200 Pharma

Develops novel oncology therapeutics using breakthrough medicinal chemistry technology and biomarker-driven assays to accelerate drug discovery and clinical approval timelines.

Culver City, US

Brian Stoltz(Director)Mark Attanasio(Director)David Chang(Director)David Licata(Director)Dennis Slamon(Director)

Figure 8museumoficecream.com

Experience-first development company creating immersive spaces that foster imagination, connection, and creativity, including the Museum of Ice Cream.

Figure8figure-8.coin

Finch Therapeuticsfinchtherapeutics.comin 𝕏

Finch is a microbiome therapeutics company that develops innovative microbiome assets designed from human microbiota transplantation studies, targeting a range of therapeutic areas.

BiotechMedical Devices

R. J. Price(Director)Jeffery A. Smisek(Director)Mark Smith(Executive Officer, Director)Andrew Mulderry(Director)Chris Lange(Director)James Burgess(Director)

Invoice2go2go.com

Subscription-based mobile app helping small business owners win jobs, track payments, and manage client payment options.

Lexense

Data-driven legal technology platform providing an end-to-end solution combining technology, funding, and expertise to efficiently resolve civil cases.

Ockam

Builds open source tools empowering developers to create trustful connected ecosystems.

Ockam fintech-blockchainockam.io

Ockam is an open-source library that enables developers to build secure communication channels with end-to-end encryption and mutual authentication across any network, cloud, or on-premises infrastructure.

CybersecurityDeveloper Tools

Olapicsocialnative.comin 𝕏

Social Native provides a platform for user-generated content (UGC) and influencer discovery that enables brands to access authentic social content across the consumer journey.

Creator EconomyMarketing TechSocial

David Shadpour(Founder & CEO)Eytan Elbaz(Co-Founder)

Orca AIorca-ai.ioin

AI-powered marine collision avoidance system providing real-time insights for data-driven maritime decisions.

OSSIOossio.ioin 𝕏

Orthopedic fixation company developing FDA-approved intelligent bone regeneration technology that is stronger than cortical bone and bioresorbable.

Praxispraxismedicines.comin 𝕏

Rad AIradai.comin 𝕏

Rad AI develops generative AI models and automation solutions specifically designed for radiology and healthcare workflows.

AI & Machine LearningEnterprise SoftwareHealthtechMedical DevicesSan Francisco, US

Dr. Jeff Chang(Co-founder)inDoktor Gurson(Co-founder)in

BoardStuart Peterson(Director)Bruce Armstrong(Director)

PartnerChris Bostick· led

SafeBreach Attack Simulation Platformsafebreach.comin 𝕏

Cybersecurity company providing automated breach and attack simulation solutions to enterprise customers.

Social Native

AI Content Creation for Brands

TechStyle Fashion Grouptechstylefashiongroup.com

Online subscription fashion retailer carrying shoes, handbags, jewelry, and denim through brands including Fabletics, Justfab, ShoeDazzle, and Savage x Fenty.

TORL BioTherapeutics

Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.

BiotechCulver City, US

Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)

PartnerChris Bostick· led

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Frequently asked questions

What stage does OCV Partners invest at?: OCV Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does OCV Partners focus on?: OCV Partners focuses on AI & Machine Learning, Biotech, Digital Health, Enterprise Software, Fintech, Healthtech, Medical Devices, PropTech, SaaS.
Where is OCV Partners located?: OCV Partners is headquartered in Los Angeles, US.
Does OCV Partners lead rounds?: Yes, OCV Partners leads investment rounds.

From the blog

visit blog ↗

Recent posts cover portfolio company developments in healthcare and maritime AI, including Rad AI's radiology generative AI products, its $60M Series C raise and RSNA Ventures partnership, and Orca AI's $72.5M raise for autonomous ship navigation. AI summary

RSNA Ventures and Rad AI Announce Strategic Partnership to Accelerate Innovation in RadiologyOct 2025The Radiological Society of North America launched RSNA Ventures and partnered with Rad AI to integrate its peer-reviewed content into radiologists' generative AI workflow at the point of care. Boosted by defense and Starlink, Orca AI pulls in $72.5M for its autonomous shipping platformMay 2025Orca AI raised a $72.5M Series B led by Brighton Park Capital for its AI autonomous ship navigation platform, driven by defense demand and Starlink connectivity. Rad AI Closes $60M Series C to Further Solidify Leadership in Healthcare Generative AIJan 2025Rad AI closed a $60M Series C led by Transformation Capital at a $525M valuation to expand its generative AI radiology reporting and follow-up solutions.

Media · Podcasts & interviews

featuring the team

Chris Bostick, OCV Partners

socaltech · Chris Bostick

Images

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.

$5K – $50M

OneVentures

OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.

$3.3M – $13.2M

AddVentures by SCG

AddVentures is the corporate venture capital arm of SCG, one of the largest industrial conglomerates in Southeast Asia. It engages with tech startups worldwide through partnerships and investments, leveraging SCG's network and resources across the region.

$1.5M – $66M

Angel Bridge Co.,Ltd.

Angel Bridge is a Japanese venture capital firm that emphasizes hands-on support as a 'supporter of entrepreneurs,' aiming to help create world-class mega ventures.

$792K – $62M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.

$500K – $15M